Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors
CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. ("Qualigen" or "the Company," Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California.
"We continue to see cancers developing resistance to current clinical agents that target a particular K-RAS mutation, and we remain optimistic that a more broad-based Pan-RAS inhibitor may help resolve these issues", commented Michael Poirier, Qualigen's Chairman and Chief Executive Officer. "The data show that our Pan-RAS inhibitors can interfere with K-RAS, H-RAS and N-RAS activity and signaling, on both mutant and wild type RAS. This suggests there could be a viable window for Pan-RAS inhibitors in patients with RAS driven tumors, as well as a potentially broader application to cancers not usually associated with RAS, such as certain classes of Ovarian, Breast, and NF1 loss driven Malignant Peripheral Nerve Sheath Tumors (MPNST)."
The Annual AACR Conference is a focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.
Highlights from this Poster
Abstract #3320 - "Novel Direct Pan-RAS Inhibitors" - Howard Donninger, Rachel Ferril, Becca von Baby, Joe Burlison, Mike Sabo, Tariq Arshad, Rob Monsen, John Trent, and Geoffrey J. Clark - Results demonstrated the compounds' role as Pan-RAS inhibitors. These compounds effectively target and disrupt the activity and signaling of various RAS mutations, including K-RAS, H-RAS, and N-RAS, impacting both mutant and wild type variants. Encouragingly, in vivo studies indicate minimal toxicity associated with these compounds, likely due to their selective suppression of RAS signaling at the administered doses. These results hint at a promising therapeutic potential for Pan-RAS inhibitors in clinical settings, emphasizing their significance in cancer treatment strategies.
About Pan-RAS
Qualigen Therapeutics has collaborated with Dr. Geoff Clark and Dr. Joe Burlison at the University of Louisville, Kentucky to develop a series of potentially highly potent compounds to take forward into preclinical development. Lead compounds are believed to suppress or block the interaction of endogenous RAS with c-RAF, and thereby influence the K-RAS, H-RAS, and N-RAS effector pathways. RAS acts as a "hub" that activates multiple effector pathways, hence blocking any single pathway may be ineffective for many RAS-driven tumor types, including pancreatic, lung, and colorectal cancers. This approach could potentially enable a differentiated, pan-RAS strategy for inhibiting the MAPK, PI3K, and RAL pathways implicated in cancer cell proliferation, survival, and differentiation.
海報包括有關新型直接 pan-RAS 抑制劑的臨床前數據
加利福尼亞州卡爾斯巴德,2024年4月10日(GLOBE NEWSWIRE)——Qualigen Therapeutics, Inc.(“Qualigen” 或 “公司”,納斯達克股票代碼:QLGN)今天宣佈,在4月5日至10日在加利福尼亞州聖地亞哥舉行的美國癌症研究協會(AACR)2024年年會上發佈了其臨床前新型直接泛RAS抑制劑的海報演示。
Qualigen董事長兼首席執行官邁克爾·普瓦里爾評論說:“我們繼續看到癌症對當前靶向特定K-RAS突變的臨床藥物產生耐藥性,我們仍然樂觀地認爲,一種基礎更廣泛的泛RAS抑制劑可能有助於解決這些問題。”“數據表明,我們的泛RAS抑制劑可以干擾突變體和野生型RAS上的K-RAS、H-RAS和N-RAS活性和信號。這表明,在RAS驅動的腫瘤患者中可能存在pan-RAS抑制劑的可行窗口,也有可能更廣泛地應用於通常與RAS無關的癌症,例如某些類別的卵巢、乳腺和NF1流失驅動的惡性周圍神經鞘瘤(MPNST)。”
年度AACR會議是癌症研究界的焦點,科學家、臨床醫生、其他醫療保健專業人員、倖存者、患者和倡導者齊聚一堂,分享癌症科學和醫學的最新進展。
這張海報的精彩片段
摘要 #3320-“新型直接泛激抑制劑”-霍華德·唐寧格、瑞秋·費里爾、貝卡·馮·巴比、喬·伯裏森、邁克·薩博、塔裏克·阿沙德、羅伯·蒙森、約翰·特倫特和傑弗裏·克拉克-結果表明這些化合物具有泛RAS抑制劑的作用。這些化合物有效地靶向和破壞各種RAS突變的活性和信號傳導,包括K-RAS、H-RAS和N-RAS,從而影響突變體和野生型變體。令人鼓舞的是,體內研究表明,與這些化合物相關的毒性微乎其微,這可能是由於它們在給藥劑量下選擇性地抑制了RAS信號。這些結果表明,pan-RAS抑制劑在臨床環境中具有廣闊的治療潛力,突顯了它們在癌症治療策略中的重要性。
關於 Pan-RAS
Qualigen Therapeutics與肯塔基州路易斯維爾大學的傑夫·克拉克博士和喬·伯裏森博士合作開發了一系列潛在的高效化合物,以推進臨床前開發。據信鉛化合物會抑制或阻斷內源性 RAS 與 c-raf 的相互作用,從而影響 K-RAS、H-RAS 和 N-RAS 效應器通路。RAS 充當激活多種效應器通路的 “樞紐”,因此阻斷任何單一途徑都可能對許多 RAS 驅動的腫瘤類型無效,包括胰腺癌、肺癌和結直腸癌。這種方法有可能實現差異化的 pan-RAS 策略,以抑制與癌細胞增殖、存活和分化有關的 MAPK、PI3K 和 RAL 通路。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧